n 2000, the Heart Outcomes Prevention Evaluation (HOPE) clinical trial demonstrated the efficacy of angio tensinconverting enzyme (ACE) inhibition in reduc ing the rates of acute myocardial infarction and stroke in highrisk patients. 1 Angiotensin II plays a major role in cardiovascular disease and its diminution by ACE inhibition is thought to directly improve primary cardiovascular outcome. However, ACE also actively participates in the regulation of the kallikreinkinin system by degrading bradykinin and generating inactive metabolites. In this regard, an augmentation of brady kinin may also explain the beneficial effects of ACE inhibition in the context of acute myocardial infarction. Bradykinin is a nonapeptide, which is derived from protein precursors called kininogens, through the action of the kallikreins. Transgenic rats overexpressing tissue kallikrein, are protected against myocar dial infarctioninduced damage, and exhibit improved cardiac remodeling. 2 These cardio protective effects are mediated by the activation of the B2 receptor because they are inhibited by the specific B2 antagonist icatibant (HOE140). Furthermore, we could recently show that transgenic rats overexpressing B2 recep tors exclusively in cardiomyocytes show improved cardiac func tions and are protected from cardiac damage induced by pressure overload (M. Bader, M. Barbosa, and J.B. Pesquero, unpublished data). The use of agonists of the B2 receptor may therefore be beneficial in cardiac diseases. Accordingly, in this issue of the American Journal of Hypertension, Marketou et al. report about the therapeutic effects of a newly developed bradykinin B2 receptor agonist reducing tissue damage and improving cardiac remodeling in acute myocardial infarction. 3 Their evidence is based on extensive histological and physiological measurements including infarct size, ejection fraction, fractional shortening and systolic blood pressure analyses. The welldescribed local vasodilatory and antifibrotic properties of the B2 receptor 4 as well as the B2induced facilitation of glucose metabolism are probably responsible for these effects. However, the authors mainly explain their results by antiapoptotic and antiinflammatory properties of the B2 receptor based on decreased terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining and a diminished expression of the proinflammatory marker, tumor necrosis factorα, respectively. Clearly, more detailed studies are warranted to elucidate the mechanism of the beneficial actions of the new drug. Moreover, a more comprehensive characteriza tion of the newly developed B2 agonist, in particular regarding its selectivity in vivo, will be necessary. In any case, B2 receptor activation is a therapeutic strategy which should be considered with caution because this receptor is involved in nociception and hyperalgesia and its activation in nerve endings of Cfibers is accompanied by one of the strongest painful sensations known. 5 Furthermore, a plethora of proinflammatory actions have been ascribed to the B2 receptor such as activation of cyclooxygenase2 and endothelial permeabilization. 5 In summary, Gavras and colleagues importantly confirmed that the activation of the B2 receptor reduces tissue dam age and improves cardiac remodeling. Thereby, the authors put forward the therapeutic value of B2 receptor agonism. However, the mechanism of action and, even more impor tantly, the possible risks of this interesting new pharmaceutical strategy merit further exploration.
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